Association between sarcopenia and a prognosis in patients undergoing percutaneous endoscopic gastrostomy

Association between sarcopenia and a prognosis in patients undergoing percutaneous endoscopic gastrostomy - Association between sarcopenia and a prognosis in patients undergoing percutaneous endoscopic gastrostomy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047005

Enrollment

127

Registered

2022-02-25

Start date

2022-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing percutaneous endoscopic gastrostomy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who meet all of the following inclusion criteria 1. Consecutive patients who underwent PEG between March 2008 to April 2020 at the Jikei University Hospital (Tokyo, Japan) 2. 20 years of age or older

Exclusion criteria

Exclusion criteria: Those who meet at least one of the following inclusion criteria 1. Patients with advanced cancer 2. Patients who underwent PEG for the purpose of decompression of the gastrointestinal tract 3. Patients in which the cross-sectional CT images at the third lumber vertebra level were not available 4. Patients with missing body height data 5. Patients who refused to participate by opting out

Design outcomes

Primary

Measure	Time frame
1) Overall survival between low and high groups of skeletal muscle mass index at the level of the third lumbar vertebra (L3-SMI)	—

Secondary

Measure	Time frame
1) Overall survival between low and high groups of psoas muscle mass index at the level of the third lumbar vertebra (L3-PMI) 2) Overall survival between low and high groups of skeletal muscle radiation attenuation at the level of the third lumbar vertebra (L3-MRA) 3) Overall survival between low and high group of L3-SMI in the covariate-balancing propensity score-matched subgroup [Cut-off values] L3-SMI: female, 29.6 cm2/m; male, 36.2 cm2/ m2 L3-PMI: female, 3.92 cm2/m2; male, 6.36 cm2/ m2 L3-MRA: female, 39.3 cm2/m2; male, 44.4 cm2/m2	—

Measure

Time frame

1) Overall survival between low and high groups of psoas muscle mass index at the level of the third lumbar vertebra (L3-PMI) 2) Overall survival between low and high groups of skeletal muscle radiation attenuation at the level of the third lumbar vertebra (L3-MRA) 3) Overall survival between low and high group of L3-SMI in the covariate-balancing propensity score-matched subgroup [Cut-off values] L3-SMI: female, 29.6 cm2/m; male, 36.2 cm2/ m2 L3-PMI: female, 3.92 cm2/m2; male, 6.36 cm2/ m2 L3-MRA: female, 39.3 cm2/m2; male, 44.4 cm2/m2

—

Countries

Japan

Contacts

Public ContactHiroto Furuhashi

The Jikei University School of Medicine Department of Endoscopy

ms04furuhashi@jikei.ac.jp0336331111

Outcome results